TGFB1 and pneumonia: When compared with the acute pneumonia group, after 7 days, TGF-β levels increased by about 19% in the group receiving MXF-22 (102.5 vs. 85.8 pg/mL; p = 0.05), suggesting a more pronounced activation of anti-inflammatory mechanisms during the early phase of treatment.